Intensive Care Network Podcasts

Professor Chad Ball: Trauma by Remote. From CICM ASM PROGRAM 2019

Dr John O’Neill: Remote Trauma. From CICM ASM PROGRAM 2019

Associate Professor Dianne Stephens: Why do we need a NCCTRC? From CICM ASM PROGRAM 2019  

Dr. Stephen Rashford: Anything a Hospital Can Do; I Can Do First. From CICM ASM PROGRAM 2019

SESSION 3 FELICITY HAWKER PAPER PRESENTATIONS Chairs: Dr Matthew Maiden & Dr Raj Goud From CICM ASM PROGRAM 2019  

Dr Nicola Curry & Dr James Winearls: Debate: Goal directed vs Ratio-based Transfusion. From CICM ASM PROGRAM 2019

Dr. Zoe McQuilten: Innovations in transfusion. From CICM ASM PROGRAM 2019

Associate Professor Samuel Galvagno: ECMO. From CICM ASM PROGRAM 2019

Professor Mark Midwinter: REBOA. From CICM ASM PROGRAM 2019

Professor Chad Ball: RAPTOR. From CICM ASM PROGRAM 2019  

CHRISTCHURCH Chair: Dr Ray Raper Dr James Mckay: What happened, what we did and how we did it… Dr Louise Hitchings: What we learned, and what we would like you to know. From CICM ASM PROGRAM 2019.  

A Podcast by Shree Basu and Corrine Balit

A Podcast by Shree Basu and Corrine Balit

A podcast by two intensivists from Westmead PICU on post resuscitation care.

Monoclonal antibodies (MAbs), guided by molecular studies and personalised medicine are changing the face of clinical medicine.  They hold the promise of controlling diseases and improving survival whilst reducing the side effects of some ‘traditional’ therapies. MAbs are being used in conditions familiar to intensivists such as asthma, invasive candidiasis, RSV infection, reversal of novel anticoagulants and clostridium difficile infection as well as in those less commonly seen by intensivists such as multiple sclerosis, migraine, rheumatoid arthritis and numerous malignancies. Side effects of MAb treatment pose particular challenges for intensivists and range from cytokine release syndrome to autoimmune states (such as colitis, endocrinopathies, skin reactions), pneumonitis, thromboemboli, and infections. Pharmcokinetic interactions of MAbs with other drugs remain poorly studied and may be immune dependent, cytokine dependent or target dependent. Our traditional approach of triaging patients for ICU, based

The incidence of cancer is increasing in line with our ageing population, with a greater number of patients requiring ICU admission for support managing complications of their malignancy, it’s therapy, or conditions unrelated to their underlying cancer. Despite these indications, the presence of a cancer diagnosis has been a common reason for refusal of ICU admission, or admission with treatment limitations.   This session will present the current epidemiology, characteristics and outcomes of patients admitted to Australian and New Zealand Intensive Care Units with cancer, and will describe the change in these outcomes across the last 17 years. Results will be reported for the most common malignancies admitted to ANZ intensive care units, common treatments and complications of malignancy will be reviewed and an agenda for further outcomes research in ICU malignancy will be proposed, with demonstration of early work in the analysis of outcomes relating to specific types of malignancy.

There have been significant developments in the diagnosis and management of ischaemic stroke.   This started with trials showing a benefit for decompressive craniectomy after a malignant hemispheric stroke in patients under 60 undergoing surgery within 48 hours.   The evolution of CT and MRI have enabled us to better image not only the ischaemic core of the stroke, but also the surrounding hypo-perfused brain at risk of ischaemic death; the penumbra. CT and MR angiography now allow rapid, non-invasive detection of occlusions in the major neck and intracranial arterial vessels.  These techniques are key to the appropriate selection of patients for therapeutic interventions aiming at rapid and effective arterial recanalisation to restore blood flow. Intravenous thrombolysis with rt-PA is effective if given early and no later than 4.5 hours. The benefit of intravenous thrombolysis for patients with severe stroke due to large artery occlusion is limited but these patients may be candidates for mechanical thrombec

People living with HIV in 2018 now have normal life expectancy if  receiving Anti-Retroviral Therapy (ART) and often require only one co-formulated pill every day to remain well.  However there are still people living with HIV who are unaware of their diagnosis; who may present with a critical illness.  Knowing who to test is essential.  The population living with HIV are also ageing and often have comorbidities.  It is vital that clinical conditions associated with HIV are recognised and for those receiving ART that significant drug-drug interactions are avoided.  Pre Exposure prophylaxis (PREP) is widely used to prevent transmission and when to consider  post exposure prophylaxis (PEP) should be understood.  Although only one person has been cured of HIV ongoing research continues.  Hepatitis C treatment has been revolutionised with Direct Acting Antiretrovirals (DAAs) that are taken in an outpatient settings, however treatment rates in Australia are in decline.  Patients living with Hepatitis C  need to be

Blood Pressure (BP) is one of the vital hemodynamic parameters that we often aim to optimize for critically ill patients. Our decisions regarding BP targets, and ensuing use (or avoidance) of vasopressor agents, may directly impact on outcomes for these patients. Despite being a fundamental tenet of critical care, there is a lack of quality evidence to suggest optimal BP targets or to guide the use of vasopressors for individual patients with shock. A mean arterial BP (MAP) of 65-70 mmHg is an often-cited initial BP target for patients during vasopressor therapy. Use of vasopressors to maintain MAP of 65 mmHg or greater remains one of the core clinical criteria in the new definition of septic shock. However, such standard targets are unlikely to be applicable to all patients, many of whom would have a basal MAP higher than 65-70 mmHg, often to a varying degree, during their usual pre-illness state. Therefore, a vasopressor therapy guided by standard BP thresholds may result in a variable degree of untreated r

Recently, several novel glucose-lowering targets have had drugs developed. This has resulted in several new drugs that have been approved for the local market to treat hyperglycaemia in patients with type 2 diabetes. This presentation will attempt to provide: A concise summary of these drugs for an Intensive Care Physician. A pragmatic framework for what the non-Endocrinology Doctor should do with these drugs whilst the patient is in, and being discharged from, the Intensive Care Unit. An outline of current trials evaluating glycaemia in the Intensive Care Unit.